Based in Sunnyvale, CA, Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer.

Sunnyvale, US
Size (employees)
1,700 (est)
Cepheid was founded in 1996 and is headquartered in Sunnyvale, US

Cepheid Office Locations

Cepheid has office in Sunnyvale
Sunnyvale, US

Cepheid Metrics

Cepheid Summary

Market capitalization

$3.9 b

Closing share price

Cepheid's current market capitalization is $3.9 b.

Cepheid Financials

Cepheid's revenue is $401.3 m in FY, 2013 which is a 14.6% decrease from the previous period.
FY, 2013FY, 2014FY, 2015


$401.3 m$470.1 m$538.6 m

Revenue growth, %


Gross profit

$193.4 m$240.8 m$268.7 m

Operating expense total

$209.4 m$274.9 m$299.6 m


($16 m)($34.1 m)($30.9 m)

Net Income

($18 m)($50.1 m)($48.5 m)

Operating cash flow

($29.7 m)$30.6 m$15.9 m

Cepheid Market Value History

Cepheid Online Presence

Cepheid News

Cepheid Company Life

You may also be interested in